InMed Pharma Advances Cannabinoid EB Therapy
Here we take a look at InMed Pharmaceuticals Inc.’s new research and development deal with ATERA SAS and why INM-750 could turn into a significant opportunity over the coming years.
The cannabis industry may be on track to exceed $50 billion over the next decade, but researchers are only beginning to discover the potential therapeutic benefits of cannabinoids. While large pharmaceutical companies are hesitant to get involved in the space, investors have several options when it comes to smaller firms conducting pre-clinical and clinical trials. These companies could offer substantial value over the coming years as the trials progress.
In this article, we will look at InMed Pharmaceuticals Inc.’s (CSE: IN) (OTCQB: IMLFF) new research and development deal with ATERA SAS of France and why INM-750 could turn into a significant opportunity over the coming years.
Epidermolysis bullosa (EB) is a group of rare diseases that causes the skin to blister or tear in response to minor injury, heat, friction, scratching, or adhesive tape. In the worst cases, these blisters may occur inside the body in the mouth or intestines. The inherited condition is caused by a defect in the anchoring between the epidermis and dermis, which results in friction and skin fragility that can cause blisters and painful sores.
There is no cure for the disease and treatment options are aimed at alleviating symptoms, such as infection and itching, as well as preventing pain and re-healing wounds. Recently, Amicus Therapeutics Inc. (NASDAQ: FOLD) acquired Scioderm’s SD-101, after completion of a Phase IIB study in 48 patients for the treatment of skin blistering and lesions, in a deal that could be worth more than $847 million. SD-101 is now in its Phase III trials.
InMed Pharma’s INM-750 product program represents a compelling alternative to SD-101 for several reasons. First, the cannabinoid compound addresses five core treatment targets – inflammation, wound healing, skin regeneration, itching, and pain – rather than just blistering and lesions. Second, there are early indications that INM-750 could potentially help reverse the painful condition by addressing the underlying cause rather than just treating the symptoms.
Cannabinoid compounds have well-documented anti-inflammatory, analgesic, and wound healing promoting properties via several mechanisms of action. InMed Pharma’s proprietary Bioinformatics Database Assessment Tool predicted cannabinoid combinations that address the hallmark EB properties, as well as cannabinoids that regulate the expression of various keratins that might compensate for the dysfunctional proteins that cause EB.
Continue reading at CannabisFN.com
Don’t forget to like and subscribe to WeedTV @yourweedtv